Advertisement
Advertisement
U.S. markets open in 7 hours 30 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1944+0.0071 (+3.79%)
At close: 3:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1873
Open0.1900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1835 - 0.2079
52 Week Range0.1110 - 0.4400
Volume163,813
Avg. Volume218,267
Market Cap78.084M
Beta (5Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-0.0810
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TETRA BIO PHARMA INC
    CPE: Lowering target price to $11.00CALLON PETROLEUM CO has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • CNW Group

    Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company's application for Orphan Drug Designation (ODD) for its investigational medicine QIXLEEF™ as a potential treatment for Complex Regional Pain Syndrome (CRPS), a chronic neuropathic pain condition.

  • PR Newswire

    Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF™.

  • PR Newswire

    REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that numerous pre-launch activities for REDUVO™ have been initiated. REDUVO™ is a cannabinoid-derived drug indicated in chemotherapy-induced nausea and vomiting (CINV). In December 2020, the Company submitted a New Drug Submission to Health Canada which is currently in its final stage of review by the regulator.

Advertisement
Advertisement